{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:42:24Z","timestamp":1792460544516,"version":"4.5.0"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ctrv.2022.102340","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:53:46Z","timestamp":1643738026000},"page":"102340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours"],"prefix":"10.1016","volume":"104","author":[{"given":"Stefania","family":"Crucitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Joosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Attili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102340_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41698-018-0055-0","article-title":"Recent advances in precision oncology research","volume":"2","author":"Bode","year":"2018","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/path.4278","article-title":"Somatic alterations as the basis for resistance to targeted therapies","volume":"232","author":"Blair","year":"2014","journal-title":"J Pathol."},{"key":"10.1016\/j.ctrv.2022.102340_b0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","article-title":"Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies","volume":"97","author":"Asi\u0107","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102340_b0020","doi-asserted-by":"crossref","first-page":"M57","DOI":"10.1016\/S0962-8924(99)01661-X","article-title":"Genetic instability and darwinian selection in tumours","volume":"9","author":"Cahill","year":"1999","journal-title":"Trends Cell Biol."},{"issue":"43","key":"10.1016\/j.ctrv.2022.102340_b0025","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1073\/pnas.1010978107","article-title":"Accumulation of driver and passenger mutations during tumor progression","volume":"107","author":"Bozic","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","article-title":"Heterogeneity in cancer: cancer stem cells versus clonal evolution","volume":"138","author":"Shackleton","year":"2009","journal-title":"Cell"},{"issue":"7467","key":"10.1016\/j.ctrv.2022.102340_b0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl Med."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0050","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/stem.2787","article-title":"Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells","volume":"36","author":"Del Re","year":"2018","journal-title":"Stem Cells."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0055","doi-asserted-by":"crossref","first-page":"e17933","DOI":"10.1371\/journal.pone.0017933","article-title":"Solving the puzzle of metastasis: the evolution of cell migration in neoplasms","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"10.1016\/j.ctrv.2022.102340_b0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1101\/gr.099622.109","article-title":"Inferring tumor progression from genomic heterogeneity","volume":"20","author":"Navin","year":"2010","journal-title":"Genome Res."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0085","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer."},{"issue":"7381","key":"10.1016\/j.ctrv.2022.102340_b0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0095","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nrg2556","article-title":"Non-genetic heterogeneity\u2013a mutation-independent driving force for the somatic evolution of tumours","volume":"10","author":"Brock","year":"2009","journal-title":"Nat Rev Genet."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3467","article-title":"Non-Darwinian dynamics in therapy-induced cancer drug resistance","volume":"4","author":"Pisco","year":"2013","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2022.102340_b0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s42003-021-02257-0","article-title":"When dormancy fuels tumour relapse","volume":"4","author":"Santos-de-Frutos","year":"2021","journal-title":"Commun Biol."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0115","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1172\/JCI96393","article-title":"TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence","volume":"128","author":"Puig","year":"2018","journal-title":"J Clin Invest."},{"issue":"7412","key":"10.1016\/j.ctrv.2022.102340_b0120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102340_b0130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10585-009-9260-0","article-title":"Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma","volume":"26","author":"Dembinski","year":"2009","journal-title":"Clin Exp Metastasis."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0135","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-12-2067","article-title":"Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer","volume":"73","author":"Lin","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctrv.2022.102340_b0140","article-title":"NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer. JCI","volume":"5","author":"Cole","year":"2020","journal-title":"Insight."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrgastro.2017.146","article-title":"Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics","volume":"15","author":"Frey","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.ctrv.2022.102340_b0150","first-page":"018","article-title":"Role of Therapy-Induced Cellular Senescence in Tumor Cells and its Modification in Radiotherapy: The Good, The Bad and The Ugly","volume":"S6","author":"Murray","year":"2013","journal-title":"J Nucl Med Radiat Ther."},{"issue":"33","key":"10.1016\/j.ctrv.2022.102340_b0155","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol."},{"issue":"11b","key":"10.1016\/j.ctrv.2022.102340_b0165","doi-asserted-by":"crossref","first-page":"E635","DOI":"10.1111\/j.1464-410X.2012.11364.x","article-title":"Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer","volume":"110","author":"Heck","year":"2012","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0170","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression","volume":"22","author":"Tripathy","year":"2004","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0175","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3892\/mco.2014.359","article-title":"Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer","volume":"2","author":"Zhuo","year":"2014","journal-title":"Mol Clin Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0180","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0185","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions","volume":"16","author":"Passaro","year":"2021","journal-title":"EGFR Mutations. J Thorac Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543781003769844","article-title":"Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma","volume":"19","author":"Cassell","year":"2010","journal-title":"Expert Opin Investig Drugs."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nature Cancer."},{"key":"10.1016\/j.ctrv.2022.102340_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0205","doi-asserted-by":"crossref","first-page":"e000724","DOI":"10.1136\/esmoopen-2020-000724","article-title":"erbB in NSCLC as a molecular target: current evidences and future directions","volume":"5","author":"Del Re","year":"2020","journal-title":"ESMO Open."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0210","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.ctrv.2022.102340_b0215","doi-asserted-by":"crossref","unstructured":"Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, et al. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget. 2017;8:13611-9.","DOI":"10.18632\/oncotarget.6957"},{"key":"10.1016\/j.ctrv.2022.102340_b0220","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijrobp.2017.01.037","article-title":"Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non\u2013Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy","volume":"98","author":"Piotrowska","year":"2017","journal-title":"International Journal of Radiation Oncology*Biology*Physics."},{"issue":"16","key":"10.1016\/j.ctrv.2022.102340_b0225","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.3390\/ijms20163951","article-title":"Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy","volume":"20","author":"Del Re","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0230","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Su","year":"2012","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0235","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay","volume":"17","author":"Arcila","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"75","key":"10.1016\/j.ctrv.2022.102340_b0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102340_b0245","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0250","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1759-7714.12382","article-title":"Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation","volume":"8","author":"Xu","year":"2017","journal-title":"Thorac Cancer."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med."},{"issue":"34","key":"10.1016\/j.ctrv.2022.102340_b0260","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0265","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0270","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cllc.2019.10.003","article-title":"Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA","volume":"21","author":"Del Re","year":"2020","journal-title":"Clin Lung Cancer."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102340_b0275","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.18632\/oncotarget.7189","article-title":"The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102340_b0280","doi-asserted-by":"crossref","first-page":"S1767","DOI":"10.1016\/j.jtho.2017.09.376","article-title":"OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms","volume":"12","author":"Oxnard","year":"2017","journal-title":"Journal of Thoracic Oncology."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102340_b0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9020","article-title":"MET amplification (amp) as a resistance mechanism to osimertinib","volume":"35","author":"Piotrowska","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0295","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.02.007","article-title":"Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib","volume":"118","author":"Wang","year":"2018","journal-title":"Lung Cancer."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2022.102340_b0310","doi-asserted-by":"crossref","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"LBA50 - Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0315","doi-asserted-by":"crossref","first-page":"e000919","DOI":"10.1136\/esmoopen-2020-000919","article-title":"Understanding EGFR heterogeneity in lung cancer","volume":"5","author":"Passaro","year":"2020","journal-title":"ESMO Open."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0320","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2012.47.7141","article-title":"Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene","volume":"32","author":"Chiari","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers10010010","article-title":"Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers","volume":"10","author":"Wei","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0330","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol Cancer."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0335","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/cancers13040699","article-title":"Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer","volume":"13","author":"Smolle","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0340","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0345","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat Med."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0350","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/JTO.0000000000000113","article-title":"Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?","volume":"9","author":"Gouji","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0355","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3892\/ijo.2014.2797","article-title":"Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer","volume":"46","author":"Kogita","year":"2015","journal-title":"Int J Oncol."},{"issue":"120","key":"10.1016\/j.ctrv.2022.102340_b0360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0365","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0370","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0375","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0380","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802\/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib","volume":"9","author":"Ou","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"22","key":"10.1016\/j.ctrv.2022.102340_b0385","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: Precision Medicine Takes on Drug Resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102340_b0395","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/JTO.0000000000000358","article-title":"Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib","volume":"9","author":"Toyokawa","year":"2014","journal-title":"J Thorac Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102340_b0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9009","article-title":"Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102340_b0405","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1541-7786.MCR-16-0211","article-title":"Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer","volume":"15","author":"Miyawaki","year":"2017","journal-title":"Mol Cancer Res."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0415","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ccell.2015.02.005","article-title":"A functional landscape of resistance to ALK inhibition in lung cancer","volume":"27","author":"Wilson","year":"2015","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102340_b0420","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-12-0392","article-title":"Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer","volume":"18","author":"Tanizaki","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"32","key":"10.1016\/j.ctrv.2022.102340_b0425","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2014.58.8293","article-title":"Intratumoral Heterogeneity of ALK-Rearranged and ALK\/EGFR Coaltered Lung Adenocarcinoma","volume":"33","author":"Cai","year":"2015","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0430","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2022.102340_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-22539-5_1","article-title":"Heterogeneity in Melanoma","volume":"167","author":"Shannan","year":"2016","journal-title":"Cancer Treat Res."},{"issue":"6892","key":"10.1016\/j.ctrv.2022.102340_b0440","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102340_b0445","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0455","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ctrv.2022.102340_b0460","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0465","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ctrv.2022.102340_b0470","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med."},{"issue":"9839","key":"10.1016\/j.ctrv.2022.102340_b0475","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0480","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors","volume":"4","author":"Rheault","year":"2013","journal-title":"ACS Med Chem Lett."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102340_b0485","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ctrv.2022.102340_b0490","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","article-title":"Development of encorafenib for BRAF-mutated advanced melanoma","volume":"30","author":"Koelblinger","year":"2018","journal-title":"Curr Opin Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0495","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS ONE"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102340_b0500","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.18632\/oncotarget.2602","article-title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma","volume":"5","author":"Spagnolo","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.ctrv.2022.102340_b0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur J Cancer."},{"issue":"7","key":"10.1016\/j.ctrv.2022.102340_b0510","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"18","key":"10.1016\/j.ctrv.2022.102340_b0515","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0520","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.15252\/emmm.201404914","article-title":"Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts","volume":"7","author":"Kemper","year":"2015","journal-title":"EMBO Mol Med."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0525","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0530","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/2159-8290.CD-12-0022","article-title":"Preexisting MEK1 exon 3 mutations in V600E\/KBRAF melanomas do not confer resistance to BRAF inhibitors","volume":"2","author":"Shi","year":"2012","journal-title":"Cancer Discov."},{"issue":"7436","key":"10.1016\/j.ctrv.2022.102340_b0535","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0540","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102340_b0545","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim Biophys Acta."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0550","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4901","article-title":"Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors","volume":"5","author":"Marusiak","year":"2014","journal-title":"Nat Commun."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0555","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0560","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2005.04.007","article-title":"Recent progress in targeting the Raf\/MEK\/ERK pathway with inhibitors in cancer drug discovery","volume":"5","author":"Thompson","year":"2005","journal-title":"Curr Opin Pharmacol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0565","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/ml200004g","article-title":"Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)","volume":"2","author":"Abe","year":"2011","journal-title":"ACS Med Chem Lett."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0570","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2022.102340_b0575","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/DDDT.S131721","article-title":"MEK inhibitors for the treatment of NRAS mutant melanoma","volume":"12","author":"Sarkisian","year":"2018","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0580","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00280-012-1988-6","article-title":"PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts","volume":"71","author":"Choo","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"issue":"9992","key":"10.1016\/j.ctrv.2022.102340_b0585","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2022.102340_b0590","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/CAD.0000000000000827","article-title":"Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report","volume":"30","author":"Kattan","year":"2019","journal-title":"Anticancer Drugs."},{"issue":"19","key":"10.1016\/j.ctrv.2022.102340_b0595","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann Transl Med."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0600","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0605","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun."},{"issue":"7","key":"10.1016\/j.ctrv.2022.102340_b0610","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","article-title":"BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0615","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"48","key":"10.1016\/j.ctrv.2022.102340_b0620","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Emery","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0625","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"issue":"7326","key":"10.1016\/j.ctrv.2022.102340_b0630","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"issue":"7326","key":"10.1016\/j.ctrv.2022.102340_b0635","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0640","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","article-title":"A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0645","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5481-z","article-title":"First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis","volume":"19","author":"Zheng","year":"2019","journal-title":"BMC Cancer."},{"issue":"23","key":"10.1016\/j.ctrv.2022.102340_b0650","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2022.102340_b0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1878-5085-4-3","article-title":"Targeted therapies in colorectal cancer-an integrative view by PPPM","volume":"4","author":"Hagan","year":"2013","journal-title":"EPMA J."},{"key":"10.1016\/j.ctrv.2022.102340_b0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/PPO.0000000000000192","article-title":"Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors","volume":"22","author":"Kircher","year":"2016","journal-title":"Cancer J."},{"key":"10.1016\/j.ctrv.2022.102340_b0665","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol."},{"issue":"14","key":"10.1016\/j.ctrv.2022.102340_b0670","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0675","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat Med."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b0680","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer","volume":"21","author":"Arena","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"224","key":"10.1016\/j.ctrv.2022.102340_b0685","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007947","article-title":"Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer","volume":"6","author":"Misale","year":"2014","journal-title":"Sci Transl Med."},{"issue":"34","key":"10.1016\/j.ctrv.2022.102340_b0690","doi-asserted-by":"crossref","first-page":"91","DOI":"10.14694\/EdBook_AM.2014.34.91","article-title":"The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning","author":"Dienstmann","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"10.1016\/j.ctrv.2022.102340_b0695","doi-asserted-by":"crossref","first-page":"102023","DOI":"10.1016\/j.ctrv.2020.102023","article-title":"Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?","volume":"86","author":"Martini","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102340_b0700","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov."},{"issue":"99","key":"10.1016\/j.ctrv.2022.102340_b0705","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0710","doi-asserted-by":"crossref","first-page":"e1004271","DOI":"10.1371\/journal.pgen.1004271","article-title":"Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing","volume":"10","author":"Mohan","year":"2014","journal-title":"PLoS Genet."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0715","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0720","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of resistance to anti-EGFR therapy in colorectal cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget."},{"issue":"13","key":"10.1016\/j.ctrv.2022.102340_b0725","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1078-0432.CCR-15-2400","article-title":"The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer","volume":"22","author":"S\u00e1nchez-Mart\u00edn","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0730","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13665","article-title":"Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer","volume":"7","author":"Van Emburgh","year":"2016","journal-title":"Nat Commun."},{"issue":"7404","key":"10.1016\/j.ctrv.2022.102340_b0735","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"7404","key":"10.1016\/j.ctrv.2022.102340_b0740","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz Jr","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0745","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mds620","article-title":"Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer","volume":"24","author":"Tougeron","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0750","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-10-3137","article-title":"Increased Detection Sensitivity for <em>KRAS<\/em> Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer","volume":"17","author":"Molinari","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102340_b0755","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3506","article-title":"Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial","volume":"39","author":"Sartore-Bianchi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0760","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0765","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/mco.2017.1270","article-title":"Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody","volume":"7","author":"Adua","year":"2017","journal-title":"Mol Clin Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0770","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdv005","article-title":"Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment","volume":"26","author":"Morelli","year":"2015","journal-title":"Ann Oncol."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0775","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/humu.22496","article-title":"Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications","volume":"35","author":"Kosmidou","year":"2014","journal-title":"Hum Mutat."},{"issue":"7572","key":"10.1016\/j.ctrv.2022.102340_b0780","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0785","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","article-title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann Oncol."},{"issue":"8","key":"10.1016\/j.ctrv.2022.102340_b0790","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102340_b0795","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3517","article-title":"HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"34","author":"Raghav","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102340_b0800","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-14-3066","article-title":"Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <em>HER2<\/em>-Amplified Gastrointestinal Carcinomas","volume":"21","author":"Leto","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102340_b0805","doi-asserted-by":"crossref","first-page":"iv39","DOI":"10.1093\/annonc\/mdw335.01","article-title":"D01* - Final Results of the HERACLES trial in HER2 amplified colorectal cancer","volume":"27","author":"Siena","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b0810","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0815","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0820","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","article-title":"Molecular heterogeneity in breast cancer: State of the science and implications for patient care","volume":"64","author":"Ellsworth","year":"2017","journal-title":"Semin Cell Dev Biol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0825","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med."},{"key":"10.1016\/j.ctrv.2022.102340_b0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther."},{"issue":"5","key":"10.1016\/j.ctrv.2022.102340_b0835","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.2015-0464","article-title":"Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer","volume":"22","author":"Kaklamani","year":"2017","journal-title":"Oncologist."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0840","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/cancers13040771","article-title":"Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy","volume":"13","author":"Mulder","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2022.102340_b0845","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2018.04.009","article-title":"Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen\/aromatase inhibitors","volume":"41","author":"Mills","year":"2018","journal-title":"Curr Opin Pharmacol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0850","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming Endocrine Resistance in Breast Cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102340_b0855","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/1078-0432.CCR-07-1399","article-title":"The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm","volume":"13","author":"Lopez-Tarruella","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2022.102340_b0860","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0865","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1878-0261.12147","article-title":"Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients","volume":"12","author":"Beije","year":"2018","journal-title":"Mol Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102340_b0870","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet."},{"key":"10.1016\/j.ctrv.2022.102340_b0875","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0880","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdy081","article-title":"ESR1 and endocrine therapy resistance: more than just mutations","volume":"29","author":"Piscuoglio","year":"2018","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b0885","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/14737140.2019.1552138","article-title":"The evolving role of receptors as predictive biomarkers for metastatic breast cancer","volume":"19","author":"Mart\u00ednez-P\u00e9rez","year":"2019","journal-title":"Expert Rev Anticancer Ther."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0890","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0895","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2022.102340_b0900","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet."},{"issue":"313","key":"10.1016\/j.ctrv.2022.102340_b0905","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med."},{"issue":"25","key":"10.1016\/j.ctrv.2022.102340_b0910","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0915","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11579","article-title":"Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant","volume":"7","author":"Spoerke","year":"2016","journal-title":"Nat Commun."},{"key":"10.1016\/j.ctrv.2022.102340_b0920","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2016.11.001","article-title":"ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients","volume":"52","author":"Angus","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0925","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Nat Commun."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b0930","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2022.102340_b0935","doi-asserted-by":"crossref","first-page":"v105","DOI":"10.1093\/annonc\/mdz242.002","article-title":"307PD - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial","volume":"30","author":"Bidard","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b0940","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-019-05365-y","article-title":"Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4\/6 inhibitors in metastatic breast cancer patients","volume":"178","author":"Del Re","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.ctrv.2022.102340_b0945","doi-asserted-by":"crossref","first-page":"105241","DOI":"10.1016\/j.phrs.2020.105241","article-title":"PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4\/6 inhibitors in metastatic breast cancer patients","volume":"163","author":"Del Re","year":"2021","journal-title":"Pharmacol Res."},{"issue":"11","key":"10.1016\/j.ctrv.2022.102340_b0950","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.ctrv.2022.102340_b0955","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2018.03.002","article-title":"Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment","volume":"125","author":"Del Re","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.ctrv.2022.102340_b0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4986365","article-title":"BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications","volume":"2020","author":"Messina","year":"2020","journal-title":"J Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0965","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12935-018-0672-2","article-title":"Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis","volume":"18","author":"Song","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ctrv.2022.102340_b0970","doi-asserted-by":"crossref","first-page":"100761","DOI":"10.1016\/j.drup.2021.100761","article-title":"Cross-resistance and drug sequence in prostate cancer","volume":"56","author":"Buck","year":"2021","journal-title":"Drug Resist Updat."},{"key":"10.1016\/j.ctrv.2022.102340_b0975","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcancer.2018.09.003","article-title":"New developments in mechanisms of prostate cancer progression","volume":"57","author":"Howard","year":"2019","journal-title":"Semin Cancer Biol."},{"issue":"19","key":"10.1016\/j.ctrv.2022.102340_b0980","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2022.102340_b0985","doi-asserted-by":"crossref","DOI":"10.1111\/bju.14792","article-title":"AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer","author":"Del Re","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b0990","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b0995","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2015.128","article-title":"Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"112","author":"Salvi","year":"2015","journal-title":"Br J Cancer."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b1000","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","article-title":"Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide","volume":"28","author":"Rathkopf","year":"2017","journal-title":"Ann Oncol."},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b1005","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b1010","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-40719-y","article-title":"Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer","volume":"9","author":"Sumiyoshi","year":"2019","journal-title":"Sci Rep."},{"issue":"41","key":"10.1016\/j.ctrv.2022.102340_b1015","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.18632\/oncotarget.3925","article-title":"Detecting predictive androgen receptor modifications in circulating prostate cancer cells","volume":"10","author":"Steinestel","year":"2019","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b1020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"312","key":"10.1016\/j.ctrv.2022.102340_b1025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med."},{"issue":"18","key":"10.1016\/j.ctrv.2022.102340_b1030","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2022.102340_b1035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-020-04133-w","article-title":"CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone","volume":"86","author":"Crucitta","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ctrv.2022.102340_b1040","doi-asserted-by":"crossref","first-page":"v346","DOI":"10.1093\/annonc\/mdz248.038","article-title":"Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)","volume":"30","author":"Aragon","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102340_b1045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b1050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102340_b1055","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","article-title":"Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study","volume":"2","author":"Ross-Adams","year":"2015","journal-title":"EBioMedicine."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102340_b1060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/ng.89","article-title":"Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer","volume":"40","author":"Gudmundsson","year":"2008","journal-title":"Nat Genet."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102340_b1065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5517","article-title":"TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC)","volume":"38","author":"Denmeade","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102340_b1070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ctrv.2022.102340_b1075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b1080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b1085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102340_b1090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctrv.2022.102340_b1095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jtbi.2015.10.019","article-title":"Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer","volume":"389","author":"Sameen","year":"2016","journal-title":"J Theor Biol."},{"issue":"10","key":"10.1016\/j.ctrv.2022.102340_b1100","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/psp4.12450","article-title":"A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors","volume":"8","author":"Yin","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b1105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13244-018-0657-7","article-title":"Radiomics and liquid biopsy in oncology: the holons of systems medicine","volume":"9","author":"Neri","year":"2018","journal-title":"Insights Imaging."},{"key":"10.1016\/j.ctrv.2022.102340_b1110","doi-asserted-by":"crossref","first-page":"105643","DOI":"10.1016\/j.phrs.2021.105643","article-title":"Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives","volume":"169","author":"Cucchiara","year":"2021","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.ctrv.2022.102340_b1115","doi-asserted-by":"crossref","first-page":"593831","DOI":"10.3389\/fonc.2020.593831","article-title":"Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer","volume":"10","author":"Cucchiara","year":"2020","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102340_b1120","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00262-020-02810-6","article-title":"A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC","volume":"70","author":"Del Re","year":"2021","journal-title":"Cancer Immunol Immunother."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:52Z","timestamp":1759656412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":224,"alternative-id":["S0305737222000032"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102340","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102340"}}